ArticleAging clinical and experimental research2025
Atherogenic index of plasma and cognitive impairment risk among hypertensive adults: evidence from a nationwide cohort study.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment is a major complication in individuals with hypertension. Emerging evidence suggests that metabolic abnormalities may contribute to its pathogenesis. This study examined the association between the atherogenic index of plasma (AIP) and risk of cognitive impairment in middle-aged and older adults with hypertension.
methodsData were from the 2011 baseline and 2018 follow-up waves of the China Health and Retirement Longitudinal Study (CHARLS). Multivariable logistic regression was used to assess the association between baseline AIP and subsequent cognitive impairment. Dose-response patterns were explored using restricted cubic spline (RCS) models, and subgroup analyses evaluated effect modification. Predictive performance of AIP versus traditional lipids was assessed by receiver operating characteristic (ROC) curves.
resultsAmong 3,739 hypertensive participants (mean age: 60.5 ± 9.1 years; 50.0% female), 43.0% developed cognitive impairment. Compared with quartile 1 (Q1), higher AIP quartiles were significantly associated with increased risk of cognitive impairment: Q2 (odds ratio [OR], 1.44; 95% confidence interval [CI], 1.15-1.80), Q3 (OR, 1.76; 95% CI, 1.40-2.20), and Q4 (OR, 1.85; 95% CI, 1.45-2.37). RCS indicated a linear dose-response (P for nonlinearity = 0.061). Subgroup analyses showed consistent associations across age, gender, body mass index, residence, and diabetes, with no significant interactions detected. AIP outperformed traditional lipid markers in predicting cognitive impairment.
conclusionElevated AIP was independently associated with an increased risk of cognitive impairment among middle-aged and older adults with hypertension, suggesting its potential as a practical biomarker for early identification of cognitive risk in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.